Highlights

  • Optiscan Imaging Ltd (ASX:OIL) has progressed its InForm digital pathology platform through a clinical study that has imaged more than 80 cases.
  • The company commenced US studies involving its InVue and InForm imaging platforms across breast and head and neck cancer applications during 2026.
  • FY26 Revenue from ordinary activities declined 52.9% to $448,769, while the annual net loss increased to $6.99 million.
  • At the time of writing this article, Optiscan Imaging Ltd (ASX:OIL) was trading at AUD 0.185, up 8.82% during today’s trading session.

At the time of writing this article, Optiscan Imaging Ltd (ASX:OIL) was trading at AUD 0.185, up 8.82% during today’s trading session. Optiscan is an Australian medical technology company developing microscopic imaging systems for digital pathology, surgery and other clinical applications. Recent activity has centred on clinical validation of its InForm and InVue platforms, progress in the US market and the commercial development of its InSpecta veterinary imaging system.

Company Business

Optiscan develops and manufactures miniaturised digital endomicroscopy technology designed to provide real-time cellular-level imaging. Its platforms are intended to support live optical biopsy and digital imaging across diagnostic, surgical, research and veterinary applications.

The company’s product portfolio includes InForm for digital pathology, InVue for precision surgery and InSpecta for veterinary medicine. The technology is designed to generate microscopic images of tissue without relying solely on conventional slide-based pathology processes.

Optiscan’s development strategy includes clinical studies intended to generate evidence for regulatory submissions and future commercial deployment. During 2026, the company expanded clinical work across pathology, breast cancer, head and neck cancer and veterinary applications.

Recent Development

In September 2026, Optiscan reported that more than 80 cases had been imaged using its InForm platform as part of a digital pathology study being conducted in a high-throughput anatomical pathology laboratory in Western Australia. The first 84 cases covered a range of tissue types and included normal, benign, inflammatory, premalignant and malignant pathologies.

Images produced using InForm are being assessed against conventional stained glass slides. The study is being used to evaluate image quality, refine imaging protocols and workflows and generate clinical evidence that may support future regulatory submissions.

Earlier in September, Optiscan initiated a US head and neck cancer study involving its imaging technologies. The development followed progress reported during July, when the company said its head and neck study was advancing ahead of schedule.

The company also signed a research agreement in July 2026 to commence a US breast cancer imaging study involving 35 patients undergoing breast-conserving surgery. The study is evaluating InVue for in-vivo surgical imaging and InForm for ex-vivo digital pathology imaging, with the aim of generating clinical evidence for planned US regulatory submissions.

InSpecta has also moved into commercial development. Optiscan submitted a regulatory dossier for the veterinary imaging device to the US Food and Drug Administration in March 2026 and subsequently launched the device into the US veterinary market in July.

Financial Performance and Sector Context

For the year ended 30 June 2026, Optiscan reported ordinary revenue of $448,769, down 52.9% from the previous financial year. The net loss attributable to shareholders increased 10.7% to $6.99 million from $6.31 million in FY25. No Dividend was declared for the period.

Net operating cash outflow increased to $7.10 million during FY26 from $6.21 million in the previous year. The company attributed the higher expenditure to increased research and development, clinical activities and commercialisation initiatives.

At 30 June 2026, net Assets stood at approximately $18.94 million, compared with $7.71 million a year earlier. Working capital, measured as current assets less current liabilities, increased to approximately $18.50 million. The change reflected, in part, the impact of capital raising activity undertaken during the financial year.

Optiscan operates in a medical technology sector where commercialisation timelines can depend on clinical validation, regulatory approvals and adoption by healthcare providers. Development expenditure can therefore precede material product revenue.

Risks to Consider

Optiscan remains exposed to regulatory and clinical execution risk as its principal medical imaging platforms progress through studies and planned regulatory pathways. Clinical results may not lead to regulatory clearance, while additional studies or documentation may be required.

Other considerations include development expenditure, cash usage, commercial adoption of new devices and the time required to convert clinical validation into recurring product revenue. Competition within medical imaging and digital pathology may also affect future market penetration.

What to Watch Next

Upcoming developments include further results from the InForm digital pathology study and continued progress across Optiscan’s US breast and head and neck cancer programs.

Investors may also monitor planned regulatory submissions for InVue and InForm, as well as the commercial development of InSpecta following its US veterinary launch.

Future quarterly updates will provide additional information on research spending, customer receipts, cash resources and progress towards regulatory and commercial milestones.

Key Insights

Optiscan entered FY27 with clinical programs progressing across digital pathology, precision surgery and veterinary imaging. The company has expanded its clinical evidence base through the InForm pathology study and US cancer imaging programs, while InSpecta has moved into the commercialisation phase.

FY26 nevertheless remained investment-intensive, with lower ordinary revenue and a wider annual loss as development expenditure increased. Clinical progress, regulatory submissions, cash usage and commercial uptake of the company’s imaging platforms remain the main factors to monitor.